Recent News

• 04.21.2025 - Compass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract Cancer
• 04.21.2025 - Compass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract Cancer
• 04.02.2025 - Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum
• 04.02.2025 - Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum
• 04.01.2025 - Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer
• 04.01.2025 - Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer
• 03.31.2025 - Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer
• 03.31.2025 - Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer
• 02.27.2025 - Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update
• 02.27.2025 - Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update

Recent Filings

• 04.11.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.11.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.11.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 04.09.2025 - 144 Report of proposed sale of securities
• 04.09.2025 - 144 Report of proposed sale of securities
• 04.08.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.08.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.01.2025 - 8-K Current report
• 04.01.2025 - EX-99.1 EX-99.1
• 03.27.2025 - S-8 Securities to be offered to employees in employee benefit plans